Miscellaneous
In the last episode of series 3, we’re joined by Anne Peters, Professor of Clinical Medicine at the Keck School of Medicine of the University of Southern California, USA, to discuss recent data on potential new therapies in development, and what this might mean in the future. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References Rosenstock J, et al. Lancet. 2021 Jun 25;S0140-6736(21)01324-6 [SURPASS-1]. Frias J P, et al. N Engl J Med. 2021 Jun 25. doi: 10.1056/NEJMoa2107519. Online ahead of print [SURPASS-2] Abstract 78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3) Abstract 80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5) Bhatt D L, et al. Late-Breaking Clinical Trials IV. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting). Disclosures: Prof. Anne Peters declares the following: Participation on an advisory board: Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Medscape, Novo Nordisk, Zealand Research Support: Dexcom, Insulet and donated devices from Abbott Diabetes Care Stock Options: Omada Health, Teladoc All conflicts of interest have been mitigated prior to this activity. Funding statement: This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.